{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:03:52Z","timestamp":1780463032637,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"ADC Therapeutics SA"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.leukres.2020.106385","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T04:44:16Z","timestamp":1591505056000},"page":"106385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Camidanlumab tesirine, an antibody-drug conjugate, in relapsed\/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2892-2643","authenticated-orcid":false,"given":"Aaron D.","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rizzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Young","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans G.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.G.","family":"Havenith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay M.","family":"Feingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wuerthner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.leukres.2020.106385_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020224","article-title":"Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia","volume":"11","author":"Ferrara","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.leukres.2020.106385_bib0010","first-page":"632","article-title":"Emerging treatments in acute myeloid leukemia: current standards and unmet challenges","volume":"15","author":"Percival","year":"2017","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2020.106385_bib0015","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2020.106385_bib0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/jcm4040665","article-title":"Current approaches in the treatment of relapsed and refractory acute myeloid leukemia","volume":"4","author":"Ramos","year":"2015","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.leukres.2020.106385_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.1461","article-title":"Incidence and survival of hematological cancers among adults ages >\/=75 years","author":"Krok-Schoen","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2020.106385_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/943823","article-title":"Challenges in treating older patients with acute myeloid leukemia","volume":"2010","author":"Eleni","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.leukres.2020.106385_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.leukres.2017.06.011","article-title":"Immunotherapy in adult acute leukemia","volume":"60","author":"Blum","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2020.106385_bib0040","article-title":"The expanding field of antibody-drug conjugates","author":"Hofland","year":"2018","journal-title":"J. Antibody Drug Conjugates"},{"issue":"4","key":"10.1016\/j.leukres.2020.106385_bib0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-019-0781-7","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets","volume":"21","author":"Stahl","year":"2019","journal-title":"Curr. Oncol. Rep."},{"issue":"12","key":"10.1016\/j.leukres.2020.106385_bib0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","article-title":"Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases","volume":"10","author":"Buckner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106385_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2007.08.005","article-title":"Interleukin-2 receptor signaling in regulatory T cell development and homeostasis","volume":"114","author":"Burchill","year":"2007","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.leukres.2020.106385_bib0060","series-title":"Simulect Summary of Product Characteristics","author":"Novartis","year":"2018"},{"issue":"9","key":"10.1016\/j.leukres.2020.106385_bib0065","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.ejca.2009.02.021","article-title":"Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML","volume":"45","author":"Terwijn","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2020.106385_bib0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.leu.2404497","article-title":"Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis","volume":"21","author":"Nakase","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2020.106385_bib0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjh.14770","article-title":"The emerging role of anti\u2010CD25 directed therapies as both immune modulators and targeted agents in cancer","volume":"179","author":"Flynn","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2020.106385_bib0080","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-Expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.leukres.2020.106385_bib0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.12109","article-title":"Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML)","volume":"160","author":"Cerny","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2020.106385_bib0090","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2012-02-414425","article-title":"CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900","volume":"120","author":"Gonen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106385_bib0095","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1038\/bcj.2014.9","article-title":"Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine","volume":"4","author":"Miltiades","year":"2014","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2020.106385_bib0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clim.2011.10.008","article-title":"Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis","volume":"142","author":"Martin","year":"2012","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.leukres.2020.106385_bib0105","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.leukres.2020.106385_bib0110","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.leukres.2020.106385_bib0115","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2020.106385_bib0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","article-title":"Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors","volume":"46","author":"Arce Vargas","year":"2017","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.leukres.2020.106385_bib0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjh.14770","article-title":"The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer","volume":"179","author":"Flynn","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"29","key":"10.1016\/j.leukres.2020.106385_bib0130","doi-asserted-by":"crossref","first-page":"47440","DOI":"10.18632\/oncotarget.17663","article-title":"Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses","volume":"8","author":"Oh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2020.106385_bib0135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1820388116","article-title":"Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity","author":"Onda","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.leukres.2020.106385_bib0140","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2020.106385_bib0145","series-title":"15th International Conference on Malignant Lymphoma (ICML), Hematological Oncology","first-page":"95","article-title":"Abstract: analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT-301, Cami) in relapsed\/refractory (r\/r) classical hodgkin lymphoma (CHL)","year":"2019"},{"issue":"24","key":"10.1016\/j.leukres.2020.106385_bib0150","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106385_bib0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2020.106385_bib0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjh.14770","article-title":"The emerging role of anti\u2010CD25 directed therapies as both immune modulators and targeted agents in cancer","volume":"179","author":"Flynn","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2020.106385_bib0165","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","volume":"132","author":"Mehdi Hamadani","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2020.106385_bib0170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2020.106385_bib0175","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Invest. New Drugs"},{"issue":"11","key":"10.1016\/j.leukres.2020.106385_bib0180","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-10-2056","article-title":"Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors","volume":"17","author":"Puzanov","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2020.106385_bib0185","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00280-009-1088-4","article-title":"A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors","volume":"65","author":"Janjigian","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106385_bib0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-018-0593-5","article-title":"CD19 CAR-T cell therapy for relapsed\/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2020.106385_bib0195","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2741\/4181","article-title":"Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin","volume":"18","author":"Cowan","year":"2013","journal-title":"Front. Biosci. (Landmark Ed)"},{"issue":"1","key":"10.1016\/j.leukres.2020.106385_bib0200","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2020.106385_bib0205","first-page":"25","article-title":"Novel immunotherapies in lymphoid malignancies, Nature reviews","volume":"13","author":"Batlevi","year":"2016","journal-title":"Clin. Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2020.106385_bib0210","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2020.106385_bib0215","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/PROM.S149420","article-title":"Impact of blinatumomab on patient outcomes in relapsed\/refractory acute lymphoblastic leukemia: evidence to date","volume":"9","author":"Hathaway","year":"2018","journal-title":"Patient Relat. Outcome Meas."},{"issue":"14","key":"10.1016\/j.leukres.2020.106385_bib0220","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"S1","key":"10.1016\/j.leukres.2020.106385_bib0225","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/ajh.25442","article-title":"Chimeric antigen receptor T cells for acute lymphoblastic leukemia","volume":"94","author":"Frey","year":"2019","journal-title":"Am. J. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:15Z","timestamp":1758934815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620300904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":45,"alternative-id":["S0145212620300904"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106385","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Camidanlumab tesirine, an antibody-drug conjugate, in relapsed\/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106385"}}